ERBB2 and neoplasm: Given the prognostic and predictive value of ER, PR, and HER2 status for stratifying patients for treatment, we determined whether tumor stromal VEGF-A expression is also a strong prognostic marker in ER+, PR+, HER2+, and TN patients.